PATENTS Court dismisses Novartis' challenge to India's patent law

Abstract

The High Court in Chennai, India, has dismissed a petition filed by Novartis challenging the constitutionality and World Trade Organization compliance of India's patent law. The Swiss drug company took exception to a stipulation that new forms of a drug cannot be patented unless they offer improved efficacy. On these grounds, India's patent office, contrary to those in nearly 40 other countries, refused to patent Novartis' anticancer drug Gleevec in 2006. Although Novartis is unlikely to appeal, the company believes the High Court's decision will have long-term negative consequences for R&D by eliminating incentives for companies to invest in India. Medical progress occurs through incremental innovation, said Paul Herrling, Novartis' head of corporate research, after the ruling. If Indian patent law does not recognize these important advances, patients will be denied new and better medicines. While the court dismissed one challenge, it left WTO itself to determine whether Indian patent law complies wi...